Cargando…

The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study

In the present study, we aimed to investigate the survival benefit from definitive local treatment (LT) for hepatocellular carcinoma patients with distant metastasis (mHCC). We retrospectively analyzed mHCC patients from Surveillance, Epidemiology, and End Results (SEER) Database. The patients’ clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Mingxue, Zhao, Yuanyuan, Liu, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882428/
https://www.ncbi.nlm.nih.gov/pubmed/29517658
http://dx.doi.org/10.1097/MD.0000000000010020
_version_ 1783311467719688192
author Su, Mingxue
Zhao, Yuanyuan
Liu, Jianjun
author_facet Su, Mingxue
Zhao, Yuanyuan
Liu, Jianjun
author_sort Su, Mingxue
collection PubMed
description In the present study, we aimed to investigate the survival benefit from definitive local treatment (LT) for hepatocellular carcinoma patients with distant metastasis (mHCC). We retrospectively analyzed mHCC patients from Surveillance, Epidemiology, and End Results (SEER) Database. The patients’ clinical and pathological characteristics were analyzed. Overall survival (OS) was calculated by Kaplan-Meier method. Independent risk factors associated with disease special mortality (DSM) were identified by multivariable regression analysis. A total of 7187 mHCC patients from SEER database were identified. A total of 258 (3.6%) patients had received surgery treatment (ST), 64 (0.9%) patients underwent radiotherapy (RT), and 6865 (95.5%) patients were identified to no surgery or radiation therapy group (NSR). Compared with the patients in NSR group, patients who received ST (hazard ratio [HR]: 0.26, 95% confidence interval [CI] 0.22–0.31, P < .001) and RT (HR: 0.51, 95% CI 0.38–0.67, P < .001) had decreased DSM. Patients with age >50 years, female, and T3 or higher stage were associated with increased DSM. The present study demonstrated the survival benefit of definitive LT in mHCC patients. However, a large randomized clinical trial to validate the role of LT in mHCC is necessary in the future.
format Online
Article
Text
id pubmed-5882428
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-58824282018-04-11 The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study Su, Mingxue Zhao, Yuanyuan Liu, Jianjun Medicine (Baltimore) 5700 In the present study, we aimed to investigate the survival benefit from definitive local treatment (LT) for hepatocellular carcinoma patients with distant metastasis (mHCC). We retrospectively analyzed mHCC patients from Surveillance, Epidemiology, and End Results (SEER) Database. The patients’ clinical and pathological characteristics were analyzed. Overall survival (OS) was calculated by Kaplan-Meier method. Independent risk factors associated with disease special mortality (DSM) were identified by multivariable regression analysis. A total of 7187 mHCC patients from SEER database were identified. A total of 258 (3.6%) patients had received surgery treatment (ST), 64 (0.9%) patients underwent radiotherapy (RT), and 6865 (95.5%) patients were identified to no surgery or radiation therapy group (NSR). Compared with the patients in NSR group, patients who received ST (hazard ratio [HR]: 0.26, 95% confidence interval [CI] 0.22–0.31, P < .001) and RT (HR: 0.51, 95% CI 0.38–0.67, P < .001) had decreased DSM. Patients with age >50 years, female, and T3 or higher stage were associated with increased DSM. The present study demonstrated the survival benefit of definitive LT in mHCC patients. However, a large randomized clinical trial to validate the role of LT in mHCC is necessary in the future. Wolters Kluwer Health 2018-03-09 /pmc/articles/PMC5882428/ /pubmed/29517658 http://dx.doi.org/10.1097/MD.0000000000010020 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5700
Su, Mingxue
Zhao, Yuanyuan
Liu, Jianjun
The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study
title The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study
title_full The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study
title_fullStr The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study
title_full_unstemmed The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study
title_short The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study
title_sort role of definitive local treatment in metastatic hepatocellular carcinoma patients: a seer-based study
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882428/
https://www.ncbi.nlm.nih.gov/pubmed/29517658
http://dx.doi.org/10.1097/MD.0000000000010020
work_keys_str_mv AT sumingxue theroleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy
AT zhaoyuanyuan theroleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy
AT liujianjun theroleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy
AT sumingxue roleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy
AT zhaoyuanyuan roleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy
AT liujianjun roleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy